Fortress Biotech Q3 revenue up 20.5%, Checkpoint sale nets $28 mln

Fortress Biotech

14/11/2025 13:42

Corrects Key Details table to remove reference to "9 months", corrects revenue to $17.6 mln from $17.02 mln in same section

Overview

Fortress Biotech Q3 net revenue rises 20.5% yr/yr

Fortress receives $28 mln from Checkpoint sale, eligible for more payments

Net income for Q3 improves from loss to profit yr/yr

Outlook

Fortress anticipates resubmitting the NDA for CUTX-101 soon

Company expects potential CVR payment up to $4.8 mln from Checkpoint sale

Fortress highlights advancement of dotinurad in Phase 3 trials for gout

Result Drivers

CHECKPOINT SALE - Fortress received $28 mln from Checkpoint sale, with potential for additional payments and royalties

EMROSI LAUNCH - Successful launch of Emrosi supported by expanded payer coverage and Phase 3 data

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Revenue
$17.6 mln
Net Income
$3.7 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Fortress Biotech Inc is $10.50, about 76.3% above its November 13 closing price of $2.49

Press Release: ID:nGNXbLvgCD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)